Role of Formyl Peptide Receptors (FPR) in Abnormal Inflammation Responses Involved in Neurodegenerative Diseases

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 15, 3 Issues, 2016

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Role of Formyl Peptide Receptors (FPR) in Abnormal Inflammation Responses Involved in Neurodegenerative Diseases

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 11(1): 20-36.

Author(s): Adriano Mollica, Azzurra Stefanucci, Roberto Costante and Francesco Pinnen.

Affiliation: University "G. d'Annunzio" of Chieti-Pescara; Faculty of Pharmacy; Dipartimento di Scienze del Farmaco; Via dei Vestini, 31; 66100 Chieti; Italy.


Neurodegenerative disorders, such as multiple sclerosis, prion diseases, Alzheimer’s disease and Parkinson’s disease are often associated with inflammatory process, which involves various components of the immune system in the central nervous system, in particular astrocytes and microglial cells. Inflammation mediators such as cytokines, leukotrienes, superoxide radicals, eicosanoids, the complement cascade, and FPR agonists (formyl peptides) may play a significant role in pro-inflammatory responses, in which infiltration of activated mononuclear phagocytes at the sites of lesion is a common feature. To prevent long-term inflammation damage, the central nervous system could be treated with antinflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs), but only few drugs were found to be effective and their therapeutic benefits is limited by side effects. Accumulating evidences suggest that targeting glia-neuron system might be a therapeutic approach in the treatment of neurodegenerative disease progression, in particular of Alzheimer’s disease. Aminopyridazine derivative discovered in unbiased cell-based screens for new synthetic compounds, have proved to be able to suppress selective glial activation responses via mechanisms distinct from NSAIDs. In this review, we report the potential involvement of FPR receptors in inflammatory responses and the potential use of their antagonists to modulate the inflammatory responses of the microglia. Recent results demonstrate that targeting of inflammatory glia cytokine pathways, can suppress Aβ-induced neuroinflammation in vivo, resulting in the attenuation of neuronal damage.


ALS, Alzheimer’s disease, FPR, Glia, Neurodegenerative diseases, Parkinson’s disease, Prion diseases, SAA, microglial cells, anti-inflammatory agents, neurodegeneration, microglial P2 receptors, macrophage, pathogenesis, Central neuron-glial .

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 1
First Page: 20
Last Page: 36
Page Count: 17
DOI: 10.2174/187152312803476246

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science